FDA Approves Prostate Health Index (PHI), a New Test for Prostate Cancer

July 8, 2012 by  
Filed under Prostate Cancer News

Recently, the US Food and Drug Administration (FDA) approved a new blood test for prostate cancer. The new test is manufactured by Beckman Coulter.

The test improves the level of result obtained when determining the prostate specific Antigen (PSA). The new test is known as the Prostate Health Index (PHI).

The FDA approved PHI for the reason that it makes for better detection of prostate cancer cells in blood, and it showed less false results when compared with what obtains in the traditional PSA tests currently used.

It would be significant you get more details on this newly approved diagnosed test.So, read more about this approval below:

A new noninvasive blood test for prostate cancer detection won the approval of the US Food and Drug Administration (FDA) on June 25, 2012. The company that makes the test, Beckman Coulter, believes that their Prostate Health Index (PHI) will not only provide better detection, but also decrease costs. The new test will be available in the United States starting this summer.

The company conducted a pivotal trial comparing their test to the standard prostate-specific antigen (PSA) currently used to detect prostate cancer, finding a 2.5-fold increase in specificity with the new test compared to the PSA test when patients had PSA values in the range of 4 ng/ml to 10 ng/ml—just the upper limit of what are considered normal PSA levels. The trial demonstrated a 31% reduction in the number of negative biopsies among patients with a positive blood test compared to those screened with a standard PSA assay.

The PHI test measures three components (PSA, free PSA, and a PSA precursor form [-2]pro-PSA) and from these three metrics, the probability of prostate cancer is calculated and used to help distinguish between a benign prostate condition that results in elevated PSA levels and prostate cancer that may require treatment. The test is aimed for men with PSA levels between 2 ng/ml and 10 ng/ml and a normal digital rectal exam.

Beckman Coulter believes that the new test will help address the recent PSA testing controversy. The US Preventive Services Task Force issued a a statement in May 2012 that the majority of men are harmed as a result of prostate cancer screening, having weighed screening and prevention with the overdiagnosis and overtreatment of slow-growing prostate cancer.

The harms include mental stress related to a positive diagnosis, and invasive biopsies that can result in fever, infection, and urinary issues. Members of the task force stated that the number of men who do not die of prostate cancer due to screening over a period of 10 to 14 years is small. The task force indicated that better testing and treatment options are necessary, recommending against regular PSA-based screening for those men with no symptoms of prostate cancer.

A cost-effectiveness analysis published at the end of last year compared the new test to the standard PSA screening, concluding that the combination of the PHI and standard PSA screening test is both cost-effective and is a better combined tool for recommendation of a prostate biopsy.

More data is still needed, however to understand whether this new test will be able to better distinguish between prostate cancer that requires treatment and slow-growing prostate cancer that can be monitored by so-called “active surveillance.” Source.

The approval of a new diagnostic test for prostate cancer is indeed a positive development in prostate cancer treatment, and it is highly welcomed. The traditional PSA test does come with some false results which may lead to unnecessary biopsies or treatments.

With the better results from PHI, all these could be avoided. Moreover, the combination of PHI and the traditional PSA test is said to be cost effective, and may be preferably recommended. Hence, there are lots of positives about this new treatment.

Finally, perhaps this test will now provide balance of opinion on the need to for blood PSA test or completely avoid it a recommended by the US Preventive Services Task Force.

Below Are Other Related Articles Among 1,000+ Prostate Cancer Articles On
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:

(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)


  1. Prostate Health Index (PHI) – a New FDA-Approved Prostate Cancer Test That Can Address the USPSTF Concerns
  2. Prostate Cancer Screening – The PSA Test and DRE Screening
  3. The Importance Of The PSA Test In Prostate Cancer Screening
  4. Diagnosis And Treatment Health Prostate Cancer – Early Screening
  5. No Prostate Cancer PSA Screening Recommended By U.S. Health Panel – Follow Up – More Condemnation From Experts – Video
  6. No Prostate Cancer PSA Screening Recommended By U.S. Health Panel
  7. Prostrate Cancer PSA Test – It’s Not Always What They Say
  8. New More Effective PSA Test Method For Detecting Prostate Cancer?
  9. Prostate Cancer Psa Test – Diagnosing And Staging
  10. Prostate Specific Antigen (PSA) Test – 7 Important Facts To Help You
  11. Why You Should Do A Prostate Cancer Psa Test Today
  12. No Prostate Cancer PSA Screening Recommended By U.S. Health Panel – Follow Up – More Speak Against It
  13. Prostate Cancer Test- Doctors Against The New Guidelines On PSA Screening
  14. PCA3 Test for Prostate Cancer Can Lessen the Inconveniences of PSA Screening
  15. Prostrate Cancer Test – Why It’s VERY Important

Comments

One Response to “FDA Approves Prostate Health Index (PHI), a New Test for Prostate Cancer”
  1. joyss says:

    It is definitely an incredible as well as beneficial bit of data. I’m happy that you just shared this kind of valuable data around. Make sure you keep us all up-to-date like this. Thank you for discussing.

Speak Your Mind

Tell us what you're thinking... !

s